




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Letter to the editor

COVID-19 vaccine, immune thrombotic thrombocytopenia, jaundice, hyperviscosity: concern on cases with underlying liver problem



We would like to share ideas on the report "COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis [1]." Aguilar et al. concluded that "We will definitely continue to be updated and "tuned-up" while further research in critical areas like etiopathogenesis and emerging therapies for VITT unfolds in this new fascinating but poorly understood arena of clinical thrombosis.....[1]." The adverse effect of COVID-19 vaccine is the present focus at present. The thrombohemostatic disturbance might occur. As noted in the editorial, there are many possible pathomechanisms [1]. We would like to add another possible underlying cause of thrombohemostatic disorder, the vaccine-induced hyperviscosity [2]. The rapid increase of immunity after vaccination might occur, and high blood viscosity can alter the normal thromohemostasis process [3]. The problem might arise in anyone receiving the vaccination. For the patient with underlying liver disease, a more risk might be expected.

Of several underlying pathophysiology, many patients with underlying liver disease usually have a high blood bilirubin level. Since hyperbilirubinemia is associated with increased blood viscosity, a patient with underlying liver disease and jaundice, such as cholangiocarcinoma or chronic active hepatitis, might have an increased chance of post COVID-19 vaccination hyperviscosity and thrombohemostatic

disorder. Closed monitoring of the possible adverse effect of COVID-19 among a person with underlying jaundice should be required.

Conflict of interest

None

References

- [1] Aguilar MP, Langner AL, Panduro A, Uribe M. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis. *Ann Hepatol* 2021;23C:100356.
- [2] Joob B, Wiwanitkit V. Expected Viscosity After COVID-19 Vaccination, Hyperviscosity and Previous COVID-19. *Clin Appl Thromb Hemost* 2021 Jan-Dec;27:10760296211020833.
- [3] Nwose EU, Richards RS, Bwiti P, Butkowski E. Serum bilirubin and lipoprotein-a: how are these associated with whole blood viscosity? *Redox Rep* 2012;17(1):8–13.

Pathum Sookaromdee*
Viroj Wiwanitkit
Private Academic Consultant, Bangkok Thailand
Honorary professor, Dr DY Patil University, Pune, India

*Correspondence: Pathum Sookaromdee, Private Academic Consultant, Bangkok Thailand
E-mail address: pathumsook@gmail.com (P. Sookaromdee).